Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00649207 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

A Phase 1 study of Neoplasm Metastasis and Central Nervous System Diseases, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 1
Development phase
80
Enrollment target
9
Study locations

NCT00649207 is a Phase 1 study of Neoplasm Metastasis and Central Nervous System Diseases that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 80 participants, below the 414-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (81% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00649207, a Phase 1 study of Neoplasm Metastasis and Central Nervous System Diseases, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 1
Development phase
80 participants
Enrollment target
9
Study locations

Study Summary

This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.

Conditions Studied

Neoplasm Metastasis Central Nervous System Diseases Brain Neoplasms Brain Diseases Nervous System Neoplasms

Interventions

  • DRUG ABT-888
  • RADIATION Whole Brain Radiation Therapy

Study Locations (9)

Other

  • Site Reference ID/Investigator# 18542 - Toronto
  • Site Reference ID/Investigator# 46322 - Ponce

Georgia

  • Site Reference ID/Investigator# 8334 - Atlanta

Illinois

  • Site Reference ID/Investigator# 52462 - Chicago

Kansas

  • Site Reference ID/Investigator# 24483 - Kansas City

Maryland

  • Site Reference ID/Investigator# 7180 - Baltimore

Michigan

  • Site Reference ID/Investigator# 19021 - Detroit

Pennsylvania

  • Site Reference ID/Investigator# 6344 - Philadelphia

Wisconsin

  • Site Reference ID/Investigator# 6653 - Madison

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2008-03
Est. Completion 2013-03
Phase Phase 1

Sponsor

AbbVie (prior sponsor, Abbott)

88 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00649207

The ClinicalTrials.gov registry entry for NCT00649207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 414-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (81% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 2 interventions - of which ABT-888 is the first listed.

NCT00649207 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Other, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT00649207 about?

NCT00649207 is a clinical study titled "A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases". This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.

What is the current status of trial NCT00649207?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2008-03. Estimated completion is 2013-03.

What conditions does trial NCT00649207 study?

This clinical trial studies the following conditions: Neoplasm Metastasis, Central Nervous System Diseases, Brain Neoplasms, Brain Diseases, Nervous System Neoplasms.

What interventions are being tested in trial NCT00649207?

The interventions under investigation include: ABT-888 (DRUG), Whole Brain Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT00649207?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00649207 being conducted?

This trial has 9 study locations across Georgia, Illinois, Kansas, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm Metastasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasm Metastasis

All registered trials for this condition

Central Nervous System Diseases

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.